Diamedica Therapeutics Inc   (DMAC)
Other Ticker:  
Price: $2.9300 $-0.07 -2.333%
Day's High: $3.0113 Week Perf: -6.98 %
Day's Low: $ 2.91 30 Day Perf: 2.81 %
Volume (M): 30 52 Wk High: $ 4.75
Volume (M$): $ 89 52 Wk Avg: $2.62
Open: $3.01 52 Wk Low: $1.46

 Market Capitalization (Millions $) 111
 Shares Outstanding (Millions) 38
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Diamedica Therapeutics Inc
Diamedica Therapeutics Inc is a biopharmaceutical company that focuses on the development of innovative therapies for patients with neurological and cardiovascular diseases. The company aims to address unmet medical needs in these areas by leveraging their expertise in protein engineering and biotherapeutics. Their research and development efforts primarily involve the development of drugs that target specific disease mechanisms or pathways. Diamedica Therapeutics Inc is committed to improving patient outcomes and enhancing the quality of life for individuals suffering from these debilitating conditions.

   Company Address: 301 Carlson Parkway, Suite 210 Minneapolis 55305 MN
   Company Phone Number: 496-5454   Stock Exchange / Ticker: NASDAQ DMAC
   DMAC is expected to report next financial results on March 27, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Diamedica Therapeutics Inc

Diamedica Therapeutics Inc. Reports Increased Operating Loss in Financial Third Quarter of 2023, Faces Challenges in a Volatile Market

Diamedica Therapeutics Inc, a major player in the Major Pharmaceutical Preparations industry, recently reported their operating loss for the most recent fiscal period. The company reported an operating loss of $-5.157 million for the quarter ending September 30, 2023. This was an increase from the operating loss of $-3.128 million in the same quarter of the previous year.
When analyzing the financial performance of a company, it is important to consider the context in which the results are presented. In the case of Diamedica Therapeutics Inc, it is clear that they have been facing some challenges in recent quarters. The increase in operating loss for the third quarter of 2023 compared to the previous year could be attributed to various factors, including a difficult operating environment or unsuccessful revenue-generating initiatives.

Diamedica Therapeutics Inc

Diamedica Therapeutics Inc sees growing business expenditures in Q2 2023, but investors concerned about operating shortfall

Diamedica Therapeutics Inc, a pharmaceutical company listed on the NASDAQ, has experienced a significant drop in shares over the past 30 days, with a decrease of -26.58%. However, despite this recent decline, the company's shares are up by 88.51% since the beginning of the year.
Investors were taken by surprise by some unexpected adjustments in the company's top-line during the April to June 30, 2023 earnings season. This led to a degree of uncertainty among investors. However, one key point of concern for investors is the operating shortfall of $-4.741 million reported by DMACs during this period.

Diamedica Therapeutics Inc

Struggling to Keep Up with Competitors in Major Pharmaceutical Industry

As a journalist reporting on financial results, I have analyzed the latest data from Diamedica Therapeutics Inc, a company in the Major Pharmaceutical Preparations industry. Unfortunately, the results are not encouraging as the company recorded a cumulative net loss of $-15 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on equity (ROE) of -46.91%.
Even more concerning is the fact that within the Major Pharmaceutical Preparations industry,
160 other companies have a higher return on equity than Diamedica Therapeutics Inc. This puts the company at a disadvantage compared to its peers, and this status quo needs to change for the company to remain competitive.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com